VIRAL VECTORS TO SUPPORT CELL & GENE THERAPIES FROM EARLY STAGES

Dr. Cristina I. Ureche



8th June 2021

Any Gene to Any Cell

SIRION Biotech founded in 2005 by Dr. Christian Thirion (CEO)


- Headquarters in Munich (Germany)
- Office branches in Boston (USA) & Paris (France)
- Global presence including Israel, UK, Switzerland, Japan and Korea
- SIRION Biotech is growing >40% p.a. (2011-2019)
- 45 employees today

Serving the entire value chain: Discovery through Preclinic to GMP

- Fast expanding global customer footprint: over 2,000 projects
- More than 300 recurring industry (biotech / big pharma) & academic clients
- Transduction technology in 20 clinical programs: Ph-I/II and Ph-III testing in Europe & USA
- First gene therapy drug market approval by a client with SIRION technology included June 2019 (EMA)
- Technology Innovation: Research & Development Partnerships








Client development over the years:

Increasing number of pure Cell & Gene Therapy developers confirms SIRION expertise in this therapeutic area



A HOLISTIC VIEW OF THERAPEUTIC DEVELOPMENT: GUIDING PROJECTS THROUGH THE ENTIRE CGT CHAIN




R&D COLLABORATIONS & LICENSING

- AAV vector evolution projects
- LentiBOOST[®] transduction enhancer with proven clinical success
- BAC technology & Ad19a/64 license opportunities for R&D and clinical applications

GMP ALLIANCES

- Vector productivity evaluation and non-GMP manufacturing of late preclinical batches
- Extended QC and documentation
- Selection of best suitable CDMO and project transfer
- GMP-compliant Process transfer and validated Assay transfer to CDMO (under development)



DISCOVERY & PRECLINICAL MANUFACTURING

- Customized viral vectors (LV, AAV, AV) for both in vitro & in vivo applications
- Different R&D scales & bulk production for preclinical animal studies
- Stringent quality controls & fast and reliable timelines

CLINICAL SUPPORT

- Clinically compliant viral vector design
- Efficacy & Safety: Optimizing the "therapeutic payload" cassette
- Non-GMP platform manufacturing process for preclinical vector evaluation
- Process development and optimization

PARNTERS

- In house consultancy
- Large animal testing /NHP studies
- CDMO network

matter of days





- Platform processes for each • viral vector type
- preclinical to clinical development

Partnerships with CDMOs for

*Provided by external collaborator

OPEN TO EXPLORE COLLABORATION OPPORTUNITIES & SYNERGIES WITH ALL INTERESTED INSTITUTIONS



RESEARCH MODEL

- Cell based assays
- Small animals (mouse, rats)
- Large animals (pigs, NHPs)

DEVELOPMENTAL STAGE

Basic Research & Drug Discovery

- Target identification & validation
- Assay development & screening
- Lead identification & optimization

Preclinical Studies

- In vivo NHP biodistributrion
- Formulation & drug delivery
- Large scale manufacturing



FIELD OF APPICATION

- Cancer
- Rare diseases
- Infectious diseases
- Immunodeficiencies
- Metabolic conditions
- Neurodegenerative & eye disorders

PARNTERSHIP TYPE

- Academia
- Research Institution
- Biotech
- Big pharma
- CMO/CDMO
- Agents/Distributors



THANK YOU!

ありがとうございました。

DANKESCHÖN





Dr. Cristina I. Ureche

Director Sales, APAC Head Discovery & Preclinical Services

ureche@sirion-biotech.de

SIRION Biotech GmbH

Am Klopferspitz 19 82152 Martinsried Germany

www.sirion-biotech.com

ANY GENE TO ANY CELL

EFFICIENT & HIGHLY SPECIALIZED VIRAL VECTOR PORTFOLIO TO TARGET ANY GENE TO ANY CELL



DISCOVERY & PRECLINICS	GENE THERAPY	CELL THERAPY
 AAV, LV, AV State of the art USPs & DSPs Approval compliant QC & documentation Professional project development Fast project implementation Advanced platform technologies RNAiONE for highly efficient shRNA identification TET inducible system 	 AAV clinical vector design Clinical compliant AAV vector development Capsid evolution, shuffled and peptide insertion AAV manufacturing Process development USP/DSP for novel vectors Non-GMP manufacturing for <i>in vivo</i> PoC studies GMP manufacturing in collaboration with CDMO partners 	 LV clinical vector design Clinical compliant LV vector development Superior LV transduction LentiBOOST[®] for ex vivo gene transfer/ CAR-T/TCR gene transfer LV manufacturing Non-GMP manufacturing for <i>in vivo</i> PoC studies GMP manufacturing in collaboration with CDMO partners



9




UNIQUE FEATURES

Highly effective, non-cytotoxic transduction enhancer Universally applicable for preclinical and clinical application of LV vectors

BENEFITS FOR DRUG DEVELOPMENT

- Increased expression levels and success of clinical trials
- Positive impact on cell proliferation for T cells
- ✓ Increased safety in line with FDA/EMA criteria
- Pharma- and GMP-grade batches for preclinical & clinical programs, and commercial use



LentiBOOST elevates lentiviral infection of IL2/OKT3 stimulated PBMCs (peripheral blood mononuclear cells).

 Anastasov N, Höfig I, Mall S, Krackhardt AM, Thirion C. Optimized Lentiviral Transduction Protocols by Use of a Poloxamer Enhancer, Spinoculation, and scFv-Antibody Fusions to VSV-G. Methods Mol Biol. 2016;1448:49-61. doi: 10.1007/978-1-4939-3753-0_4.

 Höfig I, Barth S, Salomon M, Jagusch V, Atkinson MJ, Anastasov N, Thirion C. Systematic improvement of lentivirus transduction protocols by antibody fragments fused to VSV-G as envelope glycoprotein. Biomaterials. 2014 Apr;35(13):4204-12. doi: 10.1016/j.biomaterials.2014.01.051.

3. Höfig I, Atkinson MJ, Mall S, Krackhardt AM, Thirion C, Anastasov N. Poloxamer synperonic F108 improves cellular transduction with lentiviral vectors. J Gene Med. 2012 Aug;14(8):549-60. doi: 10.1002/jgm.2653. PMID: 22887595

www.sirion-biotech.com

2021 | Business Wire SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids

www.sirion-biotech.com

2021 | Business Wire SIRION Biotech GmbH Licensed Its LentiBOOSTTM Transduction Technology to Cellectis

- 2020 | Business Wire Beam Therapeutics Licenses SIRION Biotech's LentiBOOST® Technology for its CAR-T pipeline
- 2020 | Nature, Gene Therapy SIRION LentiBOOST® transduction enhancer featured in "Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy"

2019 | Nature, Gene Therapy SIRION Biotech and Denali Therapeutics Join Forces to Develop Gene Therapies for Diseases of the Central Nervous System



celectis

EDITING LIFE





